These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25776905)

  • 1. Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs.
    Muzzio M; Hu SC; Holleran JL; Parise RA; Eiseman JL; Yellow-Duke AE; Covey JM; Glaze ER; Engelke K; Egorin MJ; McCormick DL; Beumer JH
    Cancer Chemother Pharmacol; 2015 May; 75(5):1015-23. PubMed ID: 25776905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
    Kummar S; Chen A; Gutierrez M; Pfister TD; Wang L; Redon C; Bonner WM; Yutzy W; Zhang Y; Kinders RJ; Ji J; Allen D; Covey JM; Eiseman JL; Holleran JL; Beumer JH; Rubinstein L; Collins J; Tomaszewski J; Parchment R; Pommier Y; Doroshow JH
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):73-81. PubMed ID: 27169793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.
    Holleran JL; Parise RA; Yellow-Duke AE; Egorin MJ; Eiseman JL; Covey JM; Beumer JH
    J Pharm Biomed Anal; 2010 Sep; 52(5):714-20. PubMed ID: 20236781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats.
    Han KS; Kim YG; Yoo JK; Lee JW; Lee MG
    Biopharm Drug Dispos; 1998 Nov; 19(8):493-500. PubMed ID: 9840211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
    Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of michellamine B, a naphthylisoquinoline alkaloid with in vitro activity against human immunodeficiency virus types 1 and 2, in the mouse and dog.
    Supko JG; Malspeis L
    Antimicrob Agents Chemother; 1995 Jan; 39(1):9-14. PubMed ID: 7695336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
    Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y
    Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat.
    Charnick SB; Yu Z; Athill LV; Karara AH; Tse FL; Lau DT
    Biopharm Drug Dispos; 1994 May; 15(4):317-27. PubMed ID: 8068869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
    Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.
    Jia L; Schweikart K; Tomaszewski J; Page JG; Noker PE; Buhrow SA; Reid JM; Ames MM; Munn DH
    Food Chem Toxicol; 2008 Jan; 46(1):203-11. PubMed ID: 17868966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease.
    Shetty BV; Kosa MB; Khalil DA; Webber S
    Antimicrob Agents Chemother; 1996 Jan; 40(1):110-4. PubMed ID: 8787890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
    Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
    Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
    Joerger M; Hess D; Delmonte A; Gallerani E; Fasolo A; Gianni L; Cresta S; Barbieri P; Pace S; Sessa C
    Br J Clin Pharmacol; 2015 Jul; 80(1):128-38. PubMed ID: 25580946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
    Hoch U; Staschen CM; Johnson RK; Eldon MA
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
    Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
    J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
    Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
    Abigerges D; Armand JP; Chabot GG; Bruno R; Bissery MC; Bayssas M; Klink-Alakl M; Clavel M; Catimel G
    Anticancer Drugs; 1996 Feb; 7(2):166-74. PubMed ID: 8740721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
    Braybrooke JP; Boven E; Bates NP; Ruijter R; Dobbs N; Cheverton PD; Pinedo HM; Talbot DC
    Ann Oncol; 2003 Jun; 14(6):913-21. PubMed ID: 12796030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.